Investing in the biotechnology industry can be difficult because of how volatile biotech stocks can be. News stories based on drug research, FDA approvals, and trial results can send shares soaring or plummeting in just days.
But the sector does offer solid long-term moneymakers if you know where to look...That's why we've found the best long-term stocks to buy today in biotech.
Investing in the biotechnology industry can be difficult because of how volatile biotech stocks can be. News stories based on drug research, FDA approvals, and trial results can send shares soaring or plummeting in just days.
But the sector does offer solid long-term moneymakers if you know where to look...That's why we've found the best long-term stocks to buy today in biotech.
Editor's Note: Normally this intelligence would go to paid-up members of Bill's Private Briefing, but this debut is going to be so big, and the medicine so important, that he wanted to give everyone a chance to tap this $21 billion market. The shares start trading on Thursday, Aug. 6, so there's some time to […]
just one day following the report. That's because Neogen reported a record high for both earnings and revenue.
Money Morning readers are already familiar with NEOG stock. That's because NEOG has climbed 36.5% since we first recommended it on April 22, 2014.
But the 36% gain we've seen is only the start...
Editor's Note: We're sharing this Private Briefing with you today because everyone who has a child or grandchild with a food allergy needs to know about the latest developments at this promising company. Here's Bill with more on the shares and how to play them. Shares of Neogen Corp. (Nasdaq: NEOG) soared nearly 21% on […]